Literature DB >> 31156000

Prevalence of testosterone deficiency among aging men with and without morbidities.

Juris Erenpreiss1,2, Violeta Fodina3, Rita Pozarska1, Ksenija Zubkova1, Alesja Dudorova4, Anatolijs Pozarskis5.   

Abstract

In this cross-sectional study 1852 men aged 40-70 years attending primary health care were invited to fill out the aging male symptoms (AMS) scale. Out of these, 1222 men were found positive for the AMS and agreed to provide blood samples for the general blood test, lipid profile, glucose levels, and assessment of both total and free testosterone (T) levels. Men were screened for the following morbidities and syndromes: dyslipidemia, arterial hypertension, obesity, type II diabetes, metabolic syndrome, and chronic obstructive pulmonary disease (COPD). Testosterone deficiency was diagnosed if total T ≤ 3.46 ng/mL or free T ≤ 72 pg/mL. Among all 1222 men with positive AMS, decreased blood testosterone levels were detected in 669 men (55%). A total of 402 men were found healthy and 820 men were detected with different morbidities. Out of 669 men with testosterone deficiency, only 2.8% had no co-morbidities and 97.2% were men with co-morbidities. Testosterone levels were found significantly higher among healthy men (median 4.7 ng/mL) as compared to the men with morbidities (median 2.55 ng/mL, p<.001), adjusted for age. Testosterone deficiency was detected in significantly lower proportion of 402 men without co-morbidities as compared to the 820 men with co-morbidities: in 19 men (4.7) and in 650 men (79.3%, p<.05), respectively.

Entities:  

Keywords:  Testosterone; aging men; late onset hypogonadism

Year:  2019        PMID: 31156000     DOI: 10.1080/13685538.2019.1621832

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  10 in total

Review 1.  Testosterone deficiency and the aging male.

Authors:  Gustavo M Gryzinski; Helen L Bernie
Journal:  Int J Impot Res       Date:  2022-04-07       Impact factor: 2.896

2.  Ketogenic state improves testosterone serum levels-results from a systematic review and meta-analysis.

Authors:  Chiara Furini; Giorgia Spaggiari; Manuela Simoni; Carla Greco; Daniele Santi
Journal:  Endocrine       Date:  2022-09-23       Impact factor: 3.925

3.  Metabolic Effects of Testosterone Replacement Therapy in Patients with Type 2 Diabetes Mellitus or Metabolic Syndrome: A Meta-Analysis.

Authors:  Shu-Ying Li; Ya-Ling Zhao; Yu-Fan Yang; Xi Wang; Min Nie; Xue-Yan Wu; Jiang-Feng Mao
Journal:  Int J Endocrinol       Date:  2020-09-30       Impact factor: 3.257

4.  Androgen Deficiency in Aging Males: Translation and Validation Study of the Iranian Version.

Authors:  Mansoureh Ashghali-Farahani; Alice Khachian; Parya Vakilian; Mokhtar Mahmoudi
Journal:  Iran J Nurs Midwifery Res       Date:  2021-03-05

5.  Prevalence of Low Testosterone According to Health Behavior in Older Adults Men.

Authors:  Duk Han Ko; Seong Eon Kim; Ji Young Lee
Journal:  Healthcare (Basel)       Date:  2020-12-24

6.  Prevalence of Testosterone Deficiency in Elderly Male and its Association with Frailty and Mobility at a Tertiary Care Centre.

Authors:  Vivek Aggarwal; Anil S Menon; Vishesh Verma
Journal:  Indian J Endocrinol Metab       Date:  2021-12-15

Review 7.  Low Testosterone Level and Risk of Adverse Clinical Events among Male Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Cohort Studies.

Authors:  Li Li; Huixiang Ju; Hao Jin; Hongmei Chen; Mingzhong Sun; Zhongwei Zhou
Journal:  J Healthc Eng       Date:  2022-09-10       Impact factor: 3.822

Review 8.  Testosterone Deficiency as One of the Major Endocrine Disorders in Chronic Kidney Disease.

Authors:  Katarzyna Romejko; Aleksandra Rymarz; Hanna Sadownik; Stanisław Niemczyk
Journal:  Nutrients       Date:  2022-08-21       Impact factor: 6.706

Review 9.  An Individualized Approach to Managing Testosterone Therapy in the Primary Care Setting.

Authors:  Adrian Sandra Dobs; Kevin James Campbell
Journal:  Int J Gen Med       Date:  2022-10-07

10.  FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice.

Authors:  Chi Zhang; Yun Xie; Haicheng Chen; Linyan Lv; Jiahui Yao; Min Zhang; Kai Xia; Xin Feng; Yanqing Li; Xiaoyan Liang; Xiangzhou Sun; Chunhua Deng; Guihua Liu
Journal:  Aging (Albany NY)       Date:  2020-01-20       Impact factor: 5.682

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.